VolitionRx Limited (NYSE American: VNRX) announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study achieved 97% specificity and identified 86% of cases, advancing the development of a blood-based liquid biopsy test for feline cancer. The company stated that this technology addresses a significant unmet need in veterinary medicine and represents a commercial opportunity, with potential milestone payments and future revenue generation as it works toward product commercialization and expands its presence in the growing companion animal oncology market.
The publication of this study in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment, according to the press release. VolitionRx is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information, visit the company's website at www.Volition.com. The full press release is available at https://ibn.fm/ARsEY.
The study's results are a significant step forward in the field of veterinary oncology, where early detection of cancer can greatly improve treatment outcomes and quality of life for pets. The Nu.Q Vet Feline prototype assay offers a non-invasive, blood-based testing method that could become a standard screening tool for cats suspected of having lymphoma. This development also underscores the growing interest in liquid biopsy technologies for animal health, mirroring advancements in human medicine.
VolitionRx's progress in this area could open new revenue streams and strategic partnerships within the veterinary diagnostics market. The company's focus on epigenetics provides a unique approach to cancer detection, potentially differentiating its products from existing diagnostic methods. As the company moves toward commercialization, it aims to capitalize on the increasing demand for advanced veterinary care, particularly in oncology, where pet owners are seeking more accurate and less invasive diagnostic options.
